BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.64 USD
-0.02 (-3.05%)
Updated Sep 23, 2024 03:58 PM ET
After-Market: $0.64 0.00 (-0.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 1 - 20 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
ASCO Presentation Highlights Applicability of Motixafortide In PDAC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q24 Results; APHEXDA Starts Off Nicely; Important Pancreatic Update at ASCO Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
ASFA Data Highlight Model Depicting Peak Apheresis Center Efficiency With APHEXDA + Filgrastim
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2023 Results; Pushing For APHEXDA U.S. Commercial Boost and Expansion Into Asian Territories
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
CheMo4METPANC Phase 2 Trial Kicks Off With First Patient Dosing in Expanded Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Dosing Commences in Phase 1 Motixafortide Trial in Sickle Cell Disease; Initial Data in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q23 Results; Motixafortide Building Early Commercial Footprint and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
APHEXDA Chalks Up Another Strategic Win; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Combination Trial in 1L PDAC Raises Motixafortide''s Profile; Randomized Phase 2 Enrolling
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Welcome APHEXDA to the Market; BLRX''s First FDA Approval; Price Target Upped to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q23 Results; Motixafortide Pre-Launch Activities Ramp Up With Imminent PDUFA Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q23 Results; Commercial Plans Solidify as September 9, 2023, Marks the "BioLine" for PDUFA Target Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2022 Results; U.S. Commercialization Team Finalized for APHEXDA; PDUFA Date September 9, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q22 Results; APHEXDA Commercial Readiness Activities Continue Ahead of PDUFA September 9, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
U.S. Commercial Strategy For APHEXDA (Motixafortide) Begins to Mobilize; Launch Anticipated in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q22 Results; Imminent Motixafortide NDA Submission Mid-2022; Potential Commercialization in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2021 Results; Focus Shifts Toward Pre-Launch Activities; NDA Submission on Track for Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
NDA Submission Imminent as Motixafortide Partnership Discussions Continue
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q21 Results; Visions of a Forthcoming BLA and a Likely Partnership Dancing in Our Heads
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J